Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-gingipain egg yolk antibodies (IgY-GP) are avian-derived polyclonal immunoglobulin Y (IgY) antibodies raised in laying hens immunized with purified gingipains from *Porphyromonas gingivalis*, a key Gram-negative anaerobic bacterium implicated in the pathogenesis of periodontal disease. The active ingredient targets the gingipain family of cysteine proteinases (specifically the Arg-X and Lys-X cysteine proteinases, Rgp and Kgp), which are critical virulence factors involved in bacterial colonization, tissue destruction, and immune evasion. Developed by the Nihon University School of Dentistry, IgY-GP is designed as a passive immunization strategy for periodontal disease. It is formulated as locally retained oral tablets or subgingival gels used adjunctively after scaling and root planing (SRP) to inhibit gingipain activity, reduce pocket depth, and decrease bleeding on probing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-gingipain egg yolk antibodies.